Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma

Laboratory Investigation

Volumn 88, Issue 2, 2008, Pages 98-111

  Li, Yunqing ^a   Guessous, Fadila ^a   Johnson, Elizabeth B ^a   Eberhart, Charles G ^b   Li, Xiao Nan ^c   Shu, Qing ^c   Fan, Shongshan ^d   Lal, Bachchu ^e   Laterra, John ^b,e   Schiff, David ^a   Abounader, Roger ^a,f  

^a UNIVERSITY OF VIRGINIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e KENNEDY KRIEGER INSTITUTE   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

Author keywords

c Met; c Myc; Embryonal CNS tumors; Hepatocyte growth factor; Medulloblastoma; Scatter factor

Indexed keywords

CYCLIN DEPENDENT KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROPIDIUM IODIDE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR; TYROSINE KINASE RECEPTOR;

APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; MEDULLOBLASTOMA; PRIORITY JOURNAL; RNA ISOLATION; VIRUS INFECTION; XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; BCL-X PROTEIN; BETA CATENIN; CASPASE 3; CASPASE 9; CELL CYCLE; CELL ENLARGEMENT; CELL LINE, TUMOR; CELL PROLIFERATION; CEREBELLAR NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE GROWTH FACTOR; HUMANS; MEDULLOBLASTOMA; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-MET; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 38549146069     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700702     Document Type: Article

References (50)

1. Taylor MD, Mainprize TG, Rutka JT. Molecular insight into medulloblastoma and central nervous system primitive neuroectodermal tumor biology from hereditary syndromes: a review. Neurosurgery 2000;47:888-901.
2. Wechsler-Reya R, Scott MP. The developmental biology of brain tumors. Annu Rev Neurosci 2001;24:385-428.
3. Newton HB. Review of the molecular genetics and chemotherapeutic treatment of adult and paediatric medulloblastoma. Expert Opin Investig Drugs 2001;10:2089-2104.
4. Li Y, Lal B, Kwon S, et al. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. Cancer Res 2005;65:9355-9362.
5. Schmidt EV. The role of c-myc in cellular growth control. Oncogene 1999;18:2988-2996.
6. Henriksson M, Luscher B. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv Cancer Res 1996;68:109-182.
7. Obaya AJ, Mateyak MK, Sedivy JM. Mysterious liaisons: the relationship between c-Myc and the cell cycle. Oncogene 1999;18:2934-2941.
8. Facchini LM, Penn LZ. The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J 1998;12:633-651.
9. Bouchard C, Staller P, Eilers M. Control of cell proliferation by Myc. Trends Cell Biol 1998;8:202-206.
10. Grotzer MA, Hogarty MD, Janss AJ, et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 2001;7:2425-2433.
11. Batra SK, McLendon RE, Koo JS, et al. Prognostic implications of chromosome 17p deletions in human medulloblastomas. J Neurooncol 1995;24:39-45.
12. Herms J, Neidt I, Luscher B, et al. C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer 2000;89:395-402.
13. Eberhart CG, Kratz J, Wang Y, et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 2004;63:441-449.
14. Aldosari N, Bigner SH, Burger PC, et al. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med 2002;126:540-544.
15. Bigner SH, Friedman HS, Vogelstein B, et al. Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts. Cancer Res 1990;50:2347-2350.
16. Batra SK, Rasheed BK, Bigner SH, et al. Oncogenes and anti-oncogenes in human central nervous system tumors. Lab Invest 1994;71:621-637.
17. Chiariello M, Marinissen MJ, Gutkind JS. Regulation of c-myc expression by PDGF through Rho GTPases. Nat Cell Biol 2001;3:580-586.
18. Iavarone C, Catania A, Marinissen MJ, et al. The platelet-derived growth factor controls c-myc expression through a JNK- and AP-1-dependent signaling pathway. J Biol Chem 2003;278:50024-50030.
19. Izadnegahdar MF, Rathanaswami P, Shah RM. Effects of EGF and TGFbeta1 on c-myc gene expression and DNA synthesis in embryonic hamster palate mesenchymal cells. Anat Rec 1999;254:453-464.
20. Taniguchi F, Harada T, Sakamoto Y, et al. Activation of mitogenactivated protein kinase pathway by keratinocyte growth factor or fibroblast growth factor-10 promotes cell proliferation in human endometrial carcinoma cells. J Clin Endocrinol Metab 2003;88:773-780.
21. Stearns D, Chaudhry A, Abel TW, et al. c-myc overexpression causes anaplasia in medulloblastoma. Cancer Res 2006;66:673-681.
22. Brown HG, Kepner JL, Perlman EJ, et al. 'Large cell/anaplastic' medulloblastomas: a Pediatric Oncology Group Study. J Neuropathol Exp Neurol 2000;59:857-865.
23. da Costa LT, He TC, Yu J, et al. CDX2 is mutated in a colorectal cancer with normal APC/beta-catenin signaling. Oncogene 1999;18:5010-5014.
24. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-1512.
25. Abounader R, Ranganathan S, Lal B, et al. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J Natl Cancer Inst 1999;91:1548-1556.
26. Hermeking H, Rago C, Schuhmacher M, et al. Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci USA 2000;97:2229-2234.
27. Sanchez JF, Sniderhan LF, Williamson AL, et al. Glycogen synthase kinase 3beta-mediated apoptosis of primary cortical astrocytes involves inhibition of nuclear factor kappaB signaling. Mol Cell Biol 2003;23:4649-4662.
28. Eberhart CG, Kratz JE, Schuster A, et al. Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol 2002;12:36-44.
29. Leonard JR, Cai DX, Rivet DJ, et al. Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features. J Neurosurg 2001;95:82-88.
30. Zurawel RH, Chiappa SA, Allen C, et al. Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res 1998;58:896-899.
31. Huang H, Mahler-Araujo BM, Sankila A, et al. APC mutations in sporadic medulloblastomas. Am J Pathol 2000;156:433-437.
32. Koch A, Waha A, Tonn JC, et al. Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors. Int J Cancer 2001;93:445-449.
33. Eberhart CG, Tihan T, Burger PC. Nuclear localization and mutation of beta-catenin in medulloblastomas. J Neuropathol Exp Neurol 2000;59:333-337.
34. Welm AL, Kim S, Welm BE, et al. MET and MYC cooperate in mammary tumorigenesis. Proc Natl Acad Sci USA 2005;102:4324-4329.
35. Fan S, Wang JA, Yuan RQ, et al. Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents. Oncogene 1998;17:131-141.
36. Meng Q, Mason JM, Porti D, et al. Hepatocyte growth factor decreases sensitivity to chemotherapeutic agents and stimulates cell adhesion, invasion, and migration. Biochem Biophys Res Commun 2000;274:772-779.
37. Gao M, Fan S, Goldberg ID, et al. Hepatocyte growth factor/scatter factor blocks the mitochondrial pathway of apoptosis signaling in breast cancer cells. J Biol Chem 2001;276:47257-47265.
38. Bowers DC, Fan S, Walter KA, et al. Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. Cancer Res 2000;60:4277-4283.
39. Mildner M, Eckhart L, Lengauer B, et al. Hepatocyte growth factor/scatter factor inhibits UVB-induced apoptosis of human keratinocytes but not of keratinocyte-derived cell lines via the phosphatidylinositol 3-kinase/AKT pathway. J Biol Chem 2002;277:14146-14152.
40. Bardelli A, Longati P, Albero D, et al. HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death. EMBO J 1996;15:6205-6212.
41. Xiao GH, Jeffers M, Bellacosa A, et al. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA 2001;98:247-252.
42. Conner EA, Wirth PJ, Kiss A, et al. Growth inhibition and induction of apoptosis by HGF in transformed rat liver epithelial cells. Biochem Biophys Res Commun 1997;236:396-401.
43. Shima N, Nagao M, Ogaki F, et al. Tumor cytotoxic factor/hepatocyte growth factor from human fibroblasts: cloning of its cDNA, purification and characterization of recombinant protein. Biochem Biophys Res Commun 1991;180:1151-1158.
44. Arakaki N, Kajihara T, Arakaki R, et al. Involvement of oxidative stress in tumor cytotoxic activity of hepatocyte growth factor/scatter factor. J Biol Chem 1999;274:13541-13546.
45. Matteucci E, Castoldi R, Desiderio MA. Hepatocyte growth factor induces pro-apoptotic genes in HepG2 hepatoma but not in B16-F1 melanoma cells. J Cell Physiol 2001;186:387-396.
46. Arakaki N, Kazi JA, Kazihara T, et al. Hepatocyte growth factor/scatter factor activates the apoptosis signaling pathway by increasing caspase-3 activity in sarcoma 180 cells. Biochem Biophys Res Commun 1998;245:211-215.
47. Rasola A, Anguissola S, Ferrero N, et al. Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin. Cancer Res 2004;64:1744-1750.
48. Berns K, Hijmans EM, Bernards R. Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E/CDK2 kinase activity. Oncogene 1997;15:1347-1356.
49. Maclean KH, Keller UB, Rodriguez-Galindo C, et al. c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL. Mol Cell Biol 2003;23:7256-7270.
50. Eischen CM, Packham G, Nip J, et al. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1. Oncogene 2001;20:6983-6993.